NALIRIFOX
Checked 2026-09-09
Metastatic pancreatic cancer first line
One cycle
every 14 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Liposomal irinotecan Topoisomerase I inhibitor (camptothecin prodrug) | 50 mg/m² | IV | D1 | |
Oxaliplatin Third-generation platinum (DACH-platinum) | 60 mg/m² | IV | D1 | |
Leucovorin (folinic acid) | 400 mg/m² | IV | D1 | 2-hour infusion before fluorouracil |
Fluorouracil infusion Fluoropyrimidine antimetabolite | 2,400 mg/m² | IV | D1, 2 (46 h infusion) |
Cycles
until progression
14-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Used in
Trials
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
mFOLFOX6
Adjuvant stage III colon (6 months) or metastatic colorectal and upper GI first line
every 14 days × 12
FOLFIRINOX
Metastatic pancreatic cancer, performance status 0-1
every 14 days × 12
mFOLFIRINOX (adjuvant)
Resected pancreatic cancer, fit patients, started within 12 weeks of surgery
every 14 days × 12
Gemcitabine + nab-paclitaxel
Metastatic pancreatic cancer first line; adjuvant option when FOLFIRINOX is not tolerated
every 28 days
Gemcitabine monotherapy
Frail patients or adjuvant when combinations are not tolerated
every 28 days × 6
Olaparib maintenance
Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum
every 28 days × 2